Mantle cell lymphoma medical therapy

Mantle cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mantle cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mantle cell lymphoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mantle cell lymphoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mantle cell lymphoma medical therapy
on Mantle cell lymphoma medical therapy
Mantle cell lymphoma medical therapy in the news
Blogs on Mantle cell lymphoma medical therapy
Directions to Hospitals Treating Mantle cell lymphoma
Risk calculators and risk factors for Mantle cell lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Overview

The mainstay of treatment for mantle cell lymphoma is chemotherapy. However, immunotherapy, radioimmunotherapy, targeted therapy using newer biological agents and stem cell transplantation are also used along with chemotherapy to treat the disease. Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among oncology specialists about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in clinical trials to get the latest treatments.

Medical Therapy

Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among oncology specialists about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in clinical trials to get the latest treatments.

• Different types of treatment currently being used to treat mantle cell lymphoma are as follows:

• Chemotherapy
• Immunotherapy
• Radioimmunotherapy
• Targeted therapy using newer biological agents
• Stem cell transplantation

Stage I-II:

• Radiotherapy alone or combination chemoimmunotherapy with or without radiotherapy is recommended.
• For patients with complete response(CR), clinical followup is conducted every 3-6 months for 5 years, and then on a yearly basis.
• For patients treated with radiotherapy alone initially, disease progression and relapses after a CR or partial response(PR) is treated with first-line induction therapy (recommended for stage II bulky and stage II-IV disease)
• For patients treated with chemoimmunotherapy with or without radiotherapy, disease progression and relapses after a CR or PR is treated with second-line therapy regimens (recommended for stage II bulky and stage II-IV disease)

Stage II (bulky) and Stage III-IV:

First line induction therapies:

• Aggressive therapy:

1. Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin (also known by its trade name, Adriamycin), and dexamethasone) + rituximab
2. Dose-intensified CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine) and prednisone) alternating with rituximab + high-dose cytarabine (NORDIC regimen)
3. Rituximab and methotrexate with augmented CHOP
4. Sequential R-CHOP and R-ICE (Ifosfamide, carboplatin, etoposide)
5. Alternating R-CHOP and R-DHAP (Dexamethasone, High dose Ara-C Cytarabine, Platinol)

• Less aggressive therapy:

1. Bendamustine + rituximab
2. Bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP)
3. Cladribine + rituximab
4. CHOP + rituximab (R-CHOP)
5. Modified Hyper-CVAD with rituximab maintainence in patients older than 65 years.